(Q43733522)

English

Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

chemoradiotherapy

0 references

author name string

Videtic GM

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Fung K

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Tomiak AT

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Stitt LW

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dar AR

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Truong PT

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Yu EW

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Vincent MD

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Kocha WI

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

2-3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

249-258

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of local control with prolongation in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900240-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(00)00240-3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43733522&oldid=2102910811"